Johnson & Johnson Showcases Strong Clinical Evidence for TECNIS PureSee™ IOL at ASCRS 2026
At the 2026 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting held in Washington, D.C., Johnson & Johnson unveiled compelling new clinical data supporting the performance of its TECNIS PureSee™ intraocular lens (IOL). The findings, drawn from two major studies conducted across the United States, Europe, and Asia-Pacific, reinforce the lens’s ability to deliver excellent contrast sensitivity, an extended range of vision, and high patient satisfaction.
The TECNIS PureSee™ IOL, recently approved by the U.S. Food and Drug Administration (FDA), represents a next-generation Extended Depth of Focus (EDOF) lens designed to address the visual needs of patients undergoing cataract surgery. Compared to traditional monofocal IOLs, this innovative lens offers improved intermediate vision while maintaining strong distance vision and minimizing visual disturbances.
Advancing Vision Care Through Innovation
According to Paul Lisenby, Global Head of Research and Development for Vision at Johnson & Johnson, the clinical data presented at ASCRS 2026 underscores the company’s commitment to advancing eye care through scientific rigor and innovation.
He emphasized that the TECNIS PureSee™ IOL consistently delivers high-quality visual acuity across multiple distances while maintaining low levels of visual disturbances such as glare, halos, and starbursts. These outcomes not only enhance patient experience but also strengthen surgeon confidence in adopting advanced IOL technologies.
Real-World Study Demonstrates Consistent Performance
One of the key highlights presented at the conference was a real-world, post-market observational study involving 293 patients across 19 clinical sites in Europe and Asia-Pacific. This study provided valuable insights into how the TECNIS PureSee™ IOL performs in everyday clinical settings.
Key Findings from Real-World Data
- Exceptional Distance Vision: Patients achieved a mean binocular uncorrected distance vision of approximately 20/19.
- Strong Intermediate Vision: Intermediate and corrected distance vision averaged around 20/26.
- Minimal Visual Disturbances:
- 91% reported little or no glare
- 93% experienced minimal halos
- 92% reported negligible starbursts
- High Patient Satisfaction: Overall satisfaction rates exceeded 90%.
- Reduced Dependence on Glasses:
- 96% independence for distance vision
- 95% for intermediate vision
- 61% for near vision
These findings highlight the lens’s ability to deliver a balanced visual experience, allowing patients to perform daily activities with minimal reliance on corrective eyewear.
Spectacle Independence and Quality of Vision
Another dataset presented at ASCRS focused on spectacle independence and overall visual outcomes. Results showed that patients implanted with the TECNIS PureSee™ IOL achieved excellent uncorrected and best-corrected distance vision, with many reporting freedom from glasses for most tasks.
Importantly, 93% of patients expressed satisfaction across all distances, indicating that the lens successfully meets expectations for both functional vision and quality of life.
Tolerance to Post-Operative Refractive Errors
A separate analysis examined how well the TECNIS PureSee™ IOL performs in patients with residual refractive errors following surgery. This is a critical factor, as minor refractive inaccuracies can impact visual outcomes.
Highlights:
- Mean binocular uncorrected distance vision remained strong at 20/19.
- High levels of spectacle independence were observed:
- 91% among ametropic patients
- 96% among emmetropic patients
- Patient satisfaction remained high:
- 95% for ametropic patients
- 92% for emmetropic patients
These results demonstrate that the lens maintains reliable performance even when post-operative refractive outcomes are not perfectly optimized.
U.S. Clinical Trial Confirms Efficacy
In addition to real-world evidence, Johnson & Johnson presented findings from a prospective, randomized clinical trial conducted in the United States. The study included 200 patients across nine sites and compared the TECNIS PureSee™ IOL with a standard monofocal IOL.
Key Outcomes:
- Superior Intermediate Vision: Significant improvement compared to monofocal lenses
- Maintained Distance Vision: Comparable to aspheric monofocal IOLs
- Enhanced Depth of Focus: Broader range of clear vision
- Some Near Vision Gains: Providing additional functional benefits
- Low Visual Disturbances: Minimal reports of glare, halos, and starbursts
Additionally, 94% of patients achieved distance vision corrected to 20/25 or better, while overall satisfaction reached 97%, reinforcing the lens’s strong clinical profile.
Improved Depth of Focus and Visual Range
The TECNIS PureSee™ IOL is designed using a purely refractive EDOF approach, which allows it to extend the depth of focus without introducing significant optical side effects. This design enables patients to experience smooth transitions between distance and intermediate vision, with some improvement in near vision as well.
Such advancements are particularly beneficial for individuals who want greater visual freedom after cataract surgery without compromising on clarity or comfort.
Indications and Usage
The TECNIS PureSee™ IOL is indicated for the correction of aphakia in adult patients following cataract removal, particularly in those with minimal pre-existing corneal astigmatism (less than 1 diopter). It is implanted using the TECNIS SIMPLICITY™ Delivery System and is intended for placement within the capsular bag.
The lens is specifically designed to mitigate the effects of presbyopia by extending the range of vision, offering improved intermediate acuity while maintaining high-quality distance vision.
For patients with higher levels of corneal astigmatism, the TECNIS PureSee™ Toric II IOL provides additional correction while delivering similar extended depth-of-focus benefits.
Safety Considerations and Precautions
As with any intraocular lens implantation, careful patient selection and surgical planning are essential. Physicians are advised to evaluate the benefit-risk profile for each patient, particularly in cases involving pre-existing ocular conditions.
Potential risks associated with cataract surgery include infection, inflammation, retinal detachment, and increased intraocular pressure. Additionally, improper alignment of toric lenses may reduce their effectiveness in correcting astigmatism.
Surgeons are also advised to follow strict handling and usage guidelines for the delivery system to ensure optimal performance and maintain sterility.
Commitment to Transforming Vision Care
Johnson & Johnson continues to build on its legacy of innovation in eye health, with a mission to improve vision for millions of patients worldwide. Through advancements in optical science, materials engineering, and clinical research, the company aims to redefine how people experience vision after cataract surgery.
The TECNIS PureSee™ IOL represents a significant step forward in this journey, offering patients a combination of clarity, comfort, and independence that aligns with modern lifestyle needs.
The clinical data presented at ASCRS 2026 firmly establishes the TECNIS PureSee™ IOL as a high-performing solution in the evolving landscape of cataract surgery. With strong outcomes across real-world and clinical trial settings, the lens demonstrates its ability to deliver:
- Excellent contrast sensitivity
- Extended range of vision
- Low visual disturbances
- High patient satisfaction
- Reduced dependence on glasses
As demand grows for advanced vision correction solutions, innovations like the TECNIS PureSee™ IOL are poised to play a central role in enhancing patient outcomes and shaping the future of ophthalmology.
About Johnson & Johnson
At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity. Learn more about our MedTech sector’s global scale and deep expertise in cardiovascular, orthopaedics, surgery and vision solutions
